Trial | NCT03149874  Report issue

Title

Accelerated Vaccination Schedule Against Hepatitis B Virus With Combined Hepatitis A and B Vaccine Among Hemodialysis Patients
Accelerated Vaccination Schedule Against Hepatitis B Virus With Combined Hepatitis A and B Vaccine Among Hemodialysis Patients, Does it Works?

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    114
The aim of this study is to examine the result of seroprotection using the accelerated vaccination schedule in vaccination of hemodialysis patient through using combined hepatitis A and B vaccine.
Study Started
Dec 01
2014
Primary Completion
Apr 30
2017
Study Completion
May 01
2017
Last Update
Feb 08
2023

Drug Hepatitis B recombinant DNA vaccine

Hepatitis B recombinant DNA vaccine

Drug Combined hepatitis A and B vaccine

Combined hepatitis A and B vaccine given to the patients

Hepatitis B recombinant DNA vaccine Active Comparator

Each Hepatitis B recombinant DNA vaccine vial contained 20 microgram of vaccine dose. Two vials will be intramuscularly injected one vial in each deltoid muscle on months zero, one, two and six.

Combined hepatitis A and B vaccine Active Comparator

Each one-milliliter dose of vaccine contains 720 ELISA units of inactivated hepatitis A virus and 20 mcg of recombinant HBsAg protein. One dose of vaccine also contains 0.45 mg of aluminum. Two vials will be intramuscularly injected one vial in each deltoid muscle on on days zero, seven, and 21.

Criteria 

Inclusion Criteria:

Age was above 18 years
Hemodialysis patient
All patients had undetectable hepatitis B virus surface antigen and antibody

Exclusion Criteria:

A positive serum hepatitis B virus surface antigen and antibody
patient received a previous course of hepatitis B virus vaccine
No Results Posted